• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe asthma in the US population and eligibility for mAb therapy.

作者信息

Akenroye Ayobami, McCormack Meredith, Keet Corinne

机构信息

Department of Pediatric Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, Md.

Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.

出版信息

J Allergy Clin Immunol. 2020 Apr;145(4):1295-1297.e6. doi: 10.1016/j.jaci.2019.12.009. Epub 2019 Dec 19.

DOI:10.1016/j.jaci.2019.12.009
PMID:31866437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10405858/
Abstract
摘要

相似文献

1
Severe asthma in the US population and eligibility for mAb therapy.美国人群中的重度哮喘及单克隆抗体疗法的适用性
J Allergy Clin Immunol. 2020 Apr;145(4):1295-1297.e6. doi: 10.1016/j.jaci.2019.12.009. Epub 2019 Dec 19.
2
The challenge of choosing the correct biologic for the correct asthma patient.为合适的哮喘患者选择正确生物制剂的挑战。
Ann Allergy Asthma Immunol. 2018 Oct;121(4):385-386. doi: 10.1016/j.anai.2018.08.012.
3
Biologics in the treatment of severe asthma.生物制剂在重度哮喘治疗中的应用
Allergol Immunopathol (Madr). 2017 Dec;45 Suppl 1:45-49. doi: 10.1016/j.aller.2017.09.012. Epub 2017 Nov 3.
4
Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.用于治疗哮喘的靶向白细胞介素-5、白细胞介素-4或白细胞介素-13的生物制剂——最新进展
Expert Rev Clin Immunol. 2017 Feb;13(2):143-149. doi: 10.1080/1744666X.2016.1216316. Epub 2016 Aug 2.
5
Combination biologic therapy for severe persistent asthma.重度持续性哮喘的联合生物治疗
Ann Allergy Asthma Immunol. 2019 Sep;123(3):309-311. doi: 10.1016/j.anai.2019.06.013. Epub 2019 Jun 25.
6
Severe asthma: When to resort to biological agents.严重哮喘：何时求助于生物制剂。
Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:37-39. doi: 10.1111/pai.13162.
7
Eosinophilic and Noneosinophilic Asthma.嗜酸性粒细胞性和非嗜酸性粒细胞性哮喘
Am J Respir Crit Care Med. 2018 Jan 1;197(1):22-37. doi: 10.1164/rccm.201611-2232PP.
8
Monoclonal antibodies for the treatment of refractory asthma.用于治疗难治性哮喘的单克隆抗体。
Curr Opin Pulm Med. 2014 Jan;20(1):87-94. doi: 10.1097/MCP.0000000000000007.
9
IgE and eosinophils as therapeutic targets in asthma.IgE与嗜酸性粒细胞作为哮喘的治疗靶点。
Curr Opin Allergy Clin Immunol. 2017 Feb;17(1):42-49. doi: 10.1097/ACI.0000000000000336.
10
Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5.哮喘与慢性阻塞性肺疾病、荷兰与英国假说以及白细胞介素-5的作用
Curr Opin Allergy Clin Immunol. 2018 Feb;18(1):26-31. doi: 10.1097/ACI.0000000000000409.

引用本文的文献

1
Con: clinical remission in asthma - not yet there.反对观点：哮喘的临床缓解——尚未实现。
Eur Respir Rev. 2025 Apr 2;34(176). doi: 10.1183/16000617.0182-2024. Print 2025 Apr.
2
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.2017 - 2022年重度哮喘患者的疾病负担与生物疗法可及性：国际重度哮喘注册研究分析
J Asthma Allergy. 2024 Oct 25;17:1055-1069. doi: 10.2147/JAA.S468068. eCollection 2024.
3
Allergen Immunotherapy for the Prevention and Treatment of Asthma.变应原免疫疗法用于哮喘的预防和治疗。
Clin Exp Allergy. 2025 Feb;55(2):111-141. doi: 10.1111/cea.14575. Epub 2024 Oct 4.
4
Temporal variation in the effectiveness of biologics in asthma: Effect modification by changing patient characteristics.哮喘生物制剂疗效的时间变化：改变患者特征的效应修饰。
Respir Med. 2024 Nov-Dec;234:107802. doi: 10.1016/j.rmed.2024.107802. Epub 2024 Sep 10.
5
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.意大利变应原免疫治疗登记处（RIAIT）：为过敏症专科医生提供疾病修饰治疗新视野下的新工具方案。
J Pers Med. 2024 Aug 12;14(8):854. doi: 10.3390/jpm14080854.
6
Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.种族和族裔，而非仅仅保险因素，与哮喘及相关病症中生物制剂的起始使用有关。
J Allergy Clin Immunol. 2025 Mar;155(3):1036-1044. doi: 10.1016/j.jaci.2024.08.001. Epub 2024 Aug 6.
7
Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma.非靶向代谢组学分析揭示了与哮喘患者对美泊利珠单抗和奥马珠单抗反应相关的不同代谢物。
ERJ Open Res. 2024 Aug 5;10(4). doi: 10.1183/23120541.00931-2023. eCollection 2024 Jul.
8
Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.血浆 IL-13/TNF-∝和 CXCL10/CCL17 的比值比嗜酸性粒细胞计数或免疫球蛋白 E 水平更能预测美泊利单抗和奥马珠单抗治疗哮喘的反应。
Sci Rep. 2024 May 6;14(1):10404. doi: 10.1038/s41598-024-60864-3.
9
Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.较低的肌肉生长抑制素和较高的 MUC1 水平与对美泊利珠单抗和奥马珠单抗治疗哮喘的更好反应相关：蛋白质-蛋白质相互作用分析。
Respir Res. 2023 Dec 6;24(1):305. doi: 10.1186/s12931-023-02620-1.
10
Tailored Biologics Selection in Severe Asthma.重度哮喘的个性化生物制剂选择
Tuberc Respir Dis (Seoul). 2024 Jan;87(1):12-21. doi: 10.4046/trd.2023.0103. Epub 2023 Nov 29.

本文引用的文献

1
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.按年龄和哮喘发病年龄划分的可接受美泊利珠单抗治疗的重度哮喘患者比例。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2689-2696.e2. doi: 10.1016/j.jaip.2019.05.053. Epub 2019 Jun 13.
2
Indirect treatment comparisons and biologics.间接治疗比较与生物制剂
J Allergy Clin Immunol. 2019 Jan;143(1):84-86. doi: 10.1016/j.jaci.2018.11.005.
3
Nonadherence in the era of severe asthma biologics and thermoplasty.严重哮喘生物制剂和热塑疗法时代的不依从性。
Eur Respir J. 2018 Apr 4;51(4). doi: 10.1183/13993003.01836-2017. Print 2018 Apr.
4
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.重度哮喘真实世界患者的生物治疗适用性：理想研究
J Asthma. 2018 Feb;55(2):152-160. doi: 10.1080/02770903.2017.1322611. Epub 2017 Jun 16.
5
Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma.普通人群中现患哮喘的特应性、嗜酸性粒细胞性和TH2高表达哮喘表型的重叠情况。
Ann Allergy Asthma Immunol. 2016 Jan;116(1):37-42. doi: 10.1016/j.anai.2015.10.027.
6
The prevalence of severe refractory asthma.严重难治性哮喘的患病率。
J Allergy Clin Immunol. 2015 Apr;135(4):896-902. doi: 10.1016/j.jaci.2014.08.042. Epub 2014 Oct 16.
7
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.国际 ERS/ATS 指南：严重哮喘的定义、评估和治疗。
Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12.
8
Monoclonal antibodies for the treatment of refractory asthma.用于治疗难治性哮喘的单克隆抗体。
Curr Opin Pulm Med. 2014 Jan;20(1):87-94. doi: 10.1097/MCP.0000000000000007.